PDF Download

Successful Further Development of Sepsis and Cancer Drugs

12.06.2015

Hennigsdorf, 12 June 2015 – Deutsche Biotech Innovativ AG (“DBI”) made great progress in its R&D activities in fiscal year 2014 and during the first months of 2015. The focus of its research was on innovative candidate drugs for the treatment of sepsis (severe systemic bacterial infection) and breast cancer prevention as well as cancer treatment. Within the last year and a half, the Hennigsdorf-based biotech company near Berlin was able to successfully expand its preclinical product pipeline by three drug candidates.

Hennigsdorf, 12 June 2015 – Deutsche Biotech Innovativ AG (“DBI”) made great progress in its R&D activities in fiscal year 2014 and during the first months of 2015.
The focus of its research was on innovative candidate drugs for the treatment of sepsis (severe systemic bacterial infection) and breast cancer prevention as well as cancer treatment. Within the last year and a half, the Hennigsdorf-based biotech company near Berlin was able to successfully expand its preclinical product pipeline by three drug candidates. 

Preclinical studies show promising results DBI’s lead product is a partial agonist for treating sepsis, a disease that annually affects 15 to 19 million people worldwide and is fatal for 30% of these patients. There are currently no approved medications for treating sepsis.

Adrecizumab, a humanized monoclonal antibody, developed by DBI is intended to be used for the causal and safe treatment of sepsis patients. The drug stabilizes the bioactivity of the peptide hormone adrenomedullin, thereby preventing organ failure during septic shock. After achieving very successful results during preclinical studies, DBI is currently preparing the phase I study.

In addition, DBI is researching drugs for breast cancer prevention and cancer treatment. Aprepitant and AB2302 are two promising drug candidates. Aprepitant, an NK-1 receptor antagonist, is said to trigger controlled apoptosis (programmed cell death) in the presence of abnormal cells in women with an increased risk of breast cancer. The AB2302 antibody blocks adrenomedullin and restricts tumor growth by preventing the development of blood vessels.


Annual financial statements for 2014: Higher R&D expenditures due to further development of the drug pipeline

Deutsche Biotech Innovativ AG’s net profit for fiscal year 2014 was EUR -145 k thousand compared to EUR -85 k thousand in 2013. The preclinical studies are essentially conducted by non-consolidated project companies. The DBI Group’s R&D expenditures (including project companies) in fiscal year 2014 were around EUR 1.72 million, largely due to the preparation of the phase I study for the sepsis drug Adrecizumab and the ongoing preclinical studies. As of 31 December 2014, DBI AG’s cash position amounted to around EUR 0.5 million, and around EUR 2.58 million for the project companies. In fiscal year 2014, capital measures in the scope of EUR 0.41 million were implemented at DBI AG. In the project companies, financial resources in the amount of EUR 5.25 million were made available through capital measures. Another EUR 0.16 million were contractually agreed upon at the end of 2014 and realized at the beginning of 2015. Deutsche Biotech Innovativ AG‘s 2014 annual financial statements are available for download on the company’s website:
http://www.dbi-ag.de/investor-relations/index.php 
This year’s annual general meeting will take place on 23 July 2015 in Berlin.

For more information, please contact:

Deutsche Biotech Innovativ AG 
Ms. Susanne Wallace
Tel.: +49 (0)3302 20 77 811
Email: s.wallace@dbi-ag.de


Kirchhoff Consult AG
Ms. Anja Ben Lekahl
Tel.: +49 (0)40 609 186 55
Email: anja.ben-lekahl@kirchhoff.de